Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID R SUTTON

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1447252523
CMS profile
337751
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$43,402.86

116 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID R SUTTON

NPI 1447252523 · CMS profile ID 337751

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID R SUTTON, NPI 1447252523, CMS profile ID 337751. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID R SUTTON, NPI 1447252523, CMS profile ID 337751. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID R SUTTON, NPI 1447252523, CMS profile ID 337751, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–116 of 116 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447252523?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

116 matching records · $43,402.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 116 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–116 of 116.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $800.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937106681 CMS
Lilly USA, LLC $800.0003/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937110973 CMS
Zealand Pharma US, Inc. $800.0002/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800230623 CMS
Lilly USA, LLC $800.0002/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937110381 CMS
Lilly USA, LLC $800.0002/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937111297 CMS
Lilly USA, LLC $800.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937110773 CMS
Lilly USA, LLC $400.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937110971 CMS
Lilly USA, LLC $800.0002/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937120551 CMS
Lilly USA, LLC $400.0002/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937110377 CMS
Zealand Pharma US, Inc. $1,600.0002/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 800230621 CMS
Lilly USA, LLC $800.0002/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937109707 CMS
Lilly USA, LLC $800.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937120547 CMS
Lilly USA, LLC $400.0001/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937107043 CMS
Lilly USA, LLC $800.0001/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937110767 CMS
Lilly USA, LLC $800.0001/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937111281 CMS
Lilly USA, LLC $800.0001/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937111293 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $229,100.33 546
PY2020 $123,299.81 220
PY2021 $43,402.86 116
PY2022 $141,688.88 382
PY2023 $101,076.79 371
PY2024 $81,395.56 305
PY2025 $63,037.57 288

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $317,408.78 36
PY2024 Recipient $4,329.00 1
PY2024 Principal investigator $434,126.85 62
PY2023 Principal investigator $542,750.08 214
PY2022 Principal investigator $330,800.55 84
PY2021 Principal investigator $282,569.88 23
PY2020 Principal investigator $269,596.66 12
PY2019 Principal investigator $167,008.98 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776561
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,500.00 11/25/2025 Non-covered Recipient Entity
Ecir Parent Llc
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190305035
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 11/19/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776563
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 11/19/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776565
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/18/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998741
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $333.29 11/18/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815926
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776559
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 10/01/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776551
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 10/01/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776553
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776555
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Northeast Florida Endocrine And Diabetes Associates-Downtown Jacksonville
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220776557
Principal investigator 1 Eli Lilly and Company $97,494.00 08/05/2025 Non-covered Recipient Entity
NORTHEAST RESEARCH INSTITUTE
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187886062
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,335.42 06/20/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 06/20/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510456
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,406.25 06/20/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 06/20/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510464
Principal investigator 1 Alnylam Pharmaceuticals Inc. $360.00 06/04/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 06/04/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510488
Principal investigator 1 Alnylam Pharmaceuticals Inc. $650.00 05/28/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510448
Principal investigator 1 Alnylam Pharmaceuticals Inc. $217.50 05/21/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510480
Principal investigator 1 Alnylam Pharmaceuticals Inc. $45.00 05/07/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $550.00 05/07/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510492
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,600.00 05/01/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510445
Principal investigator 1 Eli Lilly and Company $9,887.98 04/23/2025 Non-covered Recipient Entity
NORTHEAST RESEARCH INSTITUTE
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187886904
Principal investigator 1 Medtronic, Inc. $3,500.00 04/10/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,700.00 04/09/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510469
Principal investigator 1 Medtronic, Inc. $500.00 03/13/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323647
Principal investigator 1 Medtronic, Inc. $375.00 03/13/2025 Non-covered Recipient Entity
East Coast Institute For Research Llc
CIP341 IMPACT2 No dispute reported 06/30/2026 1192323649
Principal investigator 1 Eli Lilly and Company $946.30 02/25/2025 Non-covered Recipient Entity
NORTHEAST RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187886902
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,929.79 02/21/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215510426
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,195.00 02/11/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190300175
Principal investigator 1 Novartis Pharmaceuticals Corporation $547.65 01/15/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH JACKSONVILLE
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190303699
Principal investigator 1 Eli Lilly and Company $112,014.90 01/13/2025 Non-covered Recipient Entity
NORTHEAST RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187884836
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,065.50 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190300223
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,047.41 01/07/2025 Non-covered Recipient Entity
EAST COAST INSTITUTE FOR RESEARCH, LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190307127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $591.40 01/06/2025 Non-covered Recipient Entity
East Coast Institute for Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215510515